Acceleron  

Publications

  • Publication
    Sotatercept
    Dec 7, 2015
    Phase 1 Dose-Escalation Study of Sotatercept (ACE-011) in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma. The 57th Annual American Society of Hematology; December 5-8, 2015.
    + VIEW FULL Publication
  • Publication
    Luspatercept
    Dec 7, 2015
    Luspatercept (ACE-536) Reduces Disease Burden, Including Anemia, Iron Overload, and Leg Ulcers, in Adults with Beta-Thalassemia: Results from a Phase 2 Study. The 57th Annual American Society of Hematology; December 5-8, 2015.
    + VIEW FULL Publication
  • Publication
    Luspatercept
    Dec 7, 2015
    RAP-536 (Murine ACE-536/Luspatercept) Inhibits Smad2/3 Signaling and Promotes Erythroid Differentiation by Restoring GATA-1 Function in Murine β-Thalassemia. The 57th Annual American Society of Hematology; December 5-8, 2015.
    + VIEW FULL Publication
  • Publication
    Luspatercept
    Dec 7, 2015
    TGFβ1 Antagonist Inhibits Fibrosis in a Murine Model of Myelofibrosis. The 57th Annual American Society of Hematology; December 5-8, 2015.
    + VIEW FULL Publication
  • Publication
    Luspatercept
    Dec 6, 2015
    Biomarkers of Ineffective Erythropoiesis Predict Response to Luspatercept in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): Final Results from the Phase 2 PACE-MDS Study. The 57th Annual American Society of Hematology; December 5-8, 2015.
    + VIEW FULL Publication
  • Publication
    Luspatercept
    Dec 5, 2015
    Luspatercept Treatment Leads to Long Term Increases in Hemoglobin and Reductions in Transfusion Burden in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): Preliminary Results from the Phase 2 PACE-MDS Extension Study. The 57th Annual American Society of Hematology; December...
    + VIEW FULL Publication
  • Publication
    ACE-083
    Dec 5, 2015
    Phase 1 dose escalation study of ACE-083 in healthy volunteers: Preliminary results for a locally acting muscle therapeutic. The Society on Sarcopenia, Cachexia and Wasting Disorders (SCWD) Conference; December 2015.
    + VIEW FULL Publication
  • Publication
    Sotatercept
    Nov 6, 2015
    Safety and Hemoglobin Effect of Sotatercept, Administered Intravenously and Subcutaneously, for Maintenance of Hemoglobin in Hemodialysis Subjects: Interim Analysis of a Phase 2 Study. The 48th Annual American Society of Nephrology Kidney Week; November 6, 2015.
    + VIEW FULL Publication
  • Publication
    Dalantercept
    Nov 6, 2015
    The DART Study Part 1: Updated Results of Dalantercept plus Axitinib in Advanced Renal Cell Carcinoma. International Kidney Cancer Symposium; November 2015
    + VIEW FULL Publication
  • Publication
    Dalantercept
    Nov 6, 2015
    The DART Study Part 2: A Phase 2 Randomized, Double-Blind Study of Dalantercept plus Axitinib Compared to Placebo plus Axitinib in Patients with Advanced Renal Cell Carcinoma. International Kidney Cancer Symposium; November 2015
    + VIEW FULL Publication
  • Publication
    Sotatercept
    Nov 5, 2015
    Sotatercept Improves Anemia, Vascular Calcification, and Bone Loss in Patients With End-Stage Kidney Disease on Hemodialysis. American Society of Nephrology Kidney Week 2015; November 5, 2015
    + VIEW FULL Publication
  • Publication
    ACE-083
    Oct 5, 2015
    Poster Presentation – A phase 1 dose escalation study of ACE-083, a locally-acting muscle therapeutic, in healthy volunteers. FSHD International Research Consortium; October 5, 2015
    + VIEW FULL Publication
  • Publication
    ACE-2494
    Oct 1, 2015
    ACE-2494, a Novel GDF Ligand Trap, Increases Muscle Mass Upon Systemic Administration in Mice. 20th International Congress of the World Muscle Society; October 1, 2015
    + VIEW FULL Publication
  • Publication
    ACE-083
    Oct 1, 2015
    ACE-083 Increases Muscle Hypertrophy and Strength in C57BL/6 Mice . 20th International Congress of the World Muscle Society; October 1, 2015
    + VIEW FULL Publication
  • Publication
    Sotatercept
    Sep 18, 2015
    Sotatercept (ACE-011) for the Treatment of Chemotherapy-Induced Anemia in Patients with Metastatic Breast Cancer or Advanced or Metastatic Solid Tumors Treated with Platinum-Based Chemotherapeutic Regimens: Results from Two Phase 2 Studies. Supportive Care in Cancer 2015; published online Sept 14, ...
    + VIEW FULL Publication
  • Publication
    Dalantercept
    Jun 15, 2015
    Endothelial ALK1 is a Therapeutic Target for Impairing Metastatic Dissemination of Breast Cancer. Cancer Research June 15, 2015; 75(12):2445-2456
    + VIEW FULL Publication
  • Publication
    Luspatercept
    Jun 13, 2015
    Luspatercept Increases Hemoglobin and Reduces Transfusion Burden in Patients with Low or Intermediate-1 Risk MDS: Preliminary Results from the Phase 2 PACE-MDS Study. 20th Congress of the European Hematology Association; June 13, 2015
    + VIEW FULL Publication
  • Publication
    Luspatercept
    Jun 12, 2015
    Luspatercept Increases Hemoglobin and Decreases Transfusion Burden and Liver Iron Concentration in Adults with Beta-Thalassemia: Preliminary Results from a Phase 2 Study. 20th Congress of the European Hematology Association; June 12, 2015
    + VIEW FULL Publication
  • Publication
    Dalantercept
    Jun 1, 2015
    Poster – The DART Study: Dalantercept Part 2. American Society of Clinical Oncology (ASCO) Annual Meeting. June 1, 2015
    + VIEW FULL Publication
  • Publication
    Dalantercept
    Jun 1, 2015
    Poster – The DART Study: Dalantercept Part 1. American Society of Clinical Oncology (ASCO) Annual Meeting. June 1, 2015
    + VIEW FULL Publication
  • Publication
    Sotatercept
    May 30, 2015
    Quantitative Computed Tomography Results for Bone Mass and Abdominal Aortic Vascular Calcification in Hemodialysis Subjects Treated With Escalating Dose Levels of Sotatercept: Interim Analysis of ACE-011-REN-001. 52nd ERA-EDTA Congress; May 30, 2015
    + VIEW FULL Publication
  • Publication
    Sotatercept
    May 29, 2015
    Long-term Effects of 3 Dose Levels of Sotatercept Compared With Placebo for Correction of Anemia in Hemodialysis Subjects: Interim Analysis of ACE-011-REN-001. 52nd ERA-EDTA Congress; May 29, 2015
    + VIEW FULL Publication
  • Publication
    Sotatercept
    May 29, 2015
    The Role of Activin Signaling in the Pathogenesis of Renal Osteodystrophy of CKD-MBD. 52nd ERA-EDTA Congress; May 29, 2015
    + VIEW FULL Publication
  • Publication
    Luspatercept
    May 2, 2015
    Oral Presentation: Luspatercept Increases Hemoglobin and Reduces Transfusion Burden in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): Preliminary Results from a Phase 2 Study. 13th International Symposium on Myelodysplastic Syndromes (MDS), May 2, 2015
    + VIEW FULL Publication
  • Publication
    Sotatercept
    Apr 29, 2015
    Oral Presentation – A Phase 2, Dose-Finding Study of Sotatercept (ACE-011) in Patients with Lower-Risk Myelodysplastic Syndromes (MDS) or Non-Proliferative Chronic Myelomonocytic Leukemia (CMML) and Anemia Requiring Transfusion. 13th International Symposium on Myelodysplastic Syndromes (MDS)...
    + VIEW FULL Publication
  • Publication
    Dalantercept
    Feb 28, 2015
    Oral Presentation – The DART Study: Part 1 results of dose escalation and expansion cohorts of dalantercept plus axitinib in advanced renal cell carcinoma. American Society of Clinical Oncology (ASCO) Genitourinary Cancer Symposium. February 28, 2015
    + VIEW FULL Publication
  • Publication
    Dalantercept
    Feb 28, 2015
    Poster – The DART Study: Part 1 results of dose escalation and expansion cohorts of dalantercept plus axitinib in advanced renal cell carcinoma. American Society of Clinical Oncology (ASCO) Genitourinary Cancer Symposium. February 28, 2015
    + VIEW FULL Publication
  • Publication
    Dalantercept
    Jan 16, 2015
    The DASH STUDY: A Phase 1b Study of Dalantercept Plus Sorafenib in Advanced Hepatocelluar Carcinoma. American Society of Clinical Oncology (ASCO) Gastrointestinal Cancer Symposium. January 16, 2015.
    + VIEW FULL Publication